Results 251 to 260 of about 24,541,782 (296)

Cyclooxygenase‐2 in cancer: A review

Journal of Cellular Physiology, 2018
AbstractCyclooxygenase‐2 (COX‐2) is frequently expressed in many types of cancers exerting a pleiotropic and multifaceted role in genesis or promotion of carcinogenesis and cancer cell resistance to chemo‐ and radiotherapy. COX‐2 is released by cancer‐associated fibroblasts (CAFs), macrophage type 2 (M2) cells, and cancer cells to the tumor ...
Nasser Hashemi Goradel, Masoud Najafi, Eniseh Salehi, Bagher Farhood, Keywan Mortezaee   +4 more
openaire   +2 more sources

Cyclooxygenase-2 and Gastrointestinal Cancer

The Cancer Journal, 2004
The cyclooxygenase (COX) enzymes (COX-1 and COX-2) are key enzymes of prostaglandin (PG) biosynthesis. Nonselective non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the enzymatic activity of both COX-1 and COX-2. Selective COX-2 inhibitors have been developed that appear to have 50% less gastrointestinal toxicity than traditional nonselective ...
Jason R, Mann, Raymond N, DuBois
openaire   +2 more sources

Cyclooxygenase-2 and Gastric Cancer

Cancer and Metastasis Reviews, 2011
Gastric cancer remains a leading cause of cancer-related deaths worldwide, although its incidence has been steadily declining during recent decades. Expression of cyclooxygenase-2 (COX-2) is elevated in gastric carcinomas and in their precursor lesions.
Alexandra, Thiel, Johanna, Mrena, Ari, Ristimäki   +2 more
openaire   +2 more sources

Cyclooxygenase-2 as a therapeutic target

Inflammation Research, 1998
Cyclooxygenase (COX)-2 is the predominant COX isoform present at sites of inflammation, and produces prostaglandins (PG) that cause swelling and pain. However, in situations where the release of protective PGs by COX-1 has been lost, the induction of COX-2 may compensate and reduce inflammatory responses.
J A, Mitchell, T W, Evans
openaire   +2 more sources

Cyclooxygenase‐2 and gastric carcinogenesis

APMIS, 2003
Epidemiological studies have shown that the use of nonsteroid anti‐inflammatory drugs (NSAIDs) is associated with reduced risk of gastric cancer. The best‐known target of NSAIDs is the cyclooxygenase (Cox) enzyme. Two Cox genes have been cloned, of which Cox‐2 has been connected with gastric carcinogenesis.
Kirsi, Saukkonen, Johanna, Rintahaka, Anna, Sivula, Christianne J, Buskens, Bastiaan P, Van Rees, Marie-Christine, Rio, Caj, Haglund, J Jan B, Van Lanschot, G Johan A, Offerhaus, Ari, Ristimaki   +9 more
openaire   +2 more sources

THE ROLE OF CYCLOOXYGENASE-2 IN INFLAMMATION

American Journal of Therapeutics, 1995
Prostaglandins (PGs) can be synthetized via two isoforms of cyclooxygenase (COX). COX-1 is constitutively expressed in normal tissues, and its activity represent the normal physiological output of PGs. In inflammatory states, the newly discovered COX-2 is rapidly induced, and its activity accounts for the large amounts of PGs seen in inflammation.
Jaime L., Masferrer, Ben S., Zweifel, Susan M., Colburn, Richard L., Ornberg, Daniela, Salvemini, Peter, Isakson, Karen, Seibert   +6 more
openaire   +2 more sources

Mediation of Inflammation by Cyclooxygenase-2

1995
Non-steroidal antiinflammatory drugs (NSAIDs) are commonly used for the treatment of inflammation, pain, and fever. Mechanistically, these compounds are believed to act via inhibition of the enzyme cyclooxygenase (COX), which catalyzes the conversion of arachidonic acid to the prostaglandins (PGs). Although commercially available NSAIDS are efficacious
K, Seibert, J, Masferrer, Y, Zhang, S, Gregory, G, Olson, S, Hauser, K, Leahy, W, Perkins, P, Isakson   +8 more
openaire   +2 more sources

Cyclooxygenase-2: A Therapeutic Target

Annual Review of Medicine, 2002
▪ Abstract  Cyclooxygenase (COX), also known as prostaglandin endoperoxide synthase, is the key enzyme required for the conversion of arachidonic acid to prostaglandins. Two COX isoforms have been identified, COX-1 and COX-2. In many situations, the COX-1 enzyme is produced constitutively (e.g., in gastric mucosa), whereas COX-2 is highly inducible (e.
Marco E, Turini, Raymond N, DuBois
openaire   +2 more sources

[Cyclooxygenase-2 and cyclooxygenase-2 inhibitors in prostate cancer].

Zhonghua nan ke xue = National journal of andrology, 2009
Cyclooxygenase-2 (Cox-2) is over-expressed in prostate cancer (PCa) and involved in its development and progression by facilitating inflammatory response, reducing cell apoptosis, increasing angiogenesis and damaging DNA oxidation. Selective Cox-2 inhibitors suppress PCa growth through various channels and therefore have a promising application value ...
Song, Xu, Jian-Ping, Gao, Wen-Quan, Zhou
openaire   +1 more source

Lung cancer and cyclooxygenase-2

The Annals of Thoracic Surgery, 2003
Lung cancer is by far the leading cause of cancer-related death. Overall survival is poor and has not improved substantially over the last half century. It is clear that new approaches are needed and these should include prevention, screening for early detection, and novel treatments based on our understanding of the molecular biology of this disease ...
J Esteban, Castelao, Robert D, Bart, Costanzo A, DiPerna, Eric M, Sievers, Ross M, Bremner   +4 more
openaire   +2 more sources